<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802124</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HCC2016-01</org_study_id>
    <nct_id>NCT02802124</nct_id>
  </id_info>
  <brief_title>Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research project is to assess the feasibility and safety of carbon-ion
      radiotherapy for the treatment of localized Chinese hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the maximal tolerated dose (MTD) of carbon ion
      radiotherapy (CIRT) in the treatment of localized Chinese hepatocellular carcinoma with
      respective to toxicity and tumor control. Participants will be treated with CIRT with
      escalating dose regimens based on the tumor location to evaluate the maximal tolerated dose
      (MTD) in terms of acute and subacute toxicity observed during and within 3 months after the
      completion of CIRT. Primary endpoint is toxicity, second endpoint is progression-free
      survival, overall survival and tumor response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Time interval from the start of CIRT to 3 months after the completion of CIRT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of all patients</measure>
    <time_frame>From the diagnosis of localized hepatocellular carcinoma, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival of all patients</measure>
    <time_frame>From the diagnosis of localized hepatocellular carcinoma, a median of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with tumor response as assessed by RECIST 1.1</measure>
    <time_frame>Time interval from the start of CIRT to 3 months after the completion of CIRT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>carbon-ion radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels [55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx] are planned within the Phase I part.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>proton plus carbon-ion radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For tumor location which is adjacent to gastrointestine (less than 1 cm).We use proton plus carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.
Four dose levels (proton 50GyE/25Fx+ carbon 15GyE/5Fx,proton 34GyE/17Fx+ carbon 30GyE/10Fx, proton 18GyE/9Fx+ carbon 45GyE/15Fx,carbon 60GyE/20Fx ) are planned within the Phase I part.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon-ion radiotherapy alone</intervention_name>
    <arm_group_label>carbon-ion radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>proton plus carbon-ion radiotherapy</intervention_name>
    <arm_group_label>proton plus carbon-ion radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis of HCC
             according to American association for the study of liver diseases （AASLD）-guidelines
             or clinical diagnosis criteria based on Alpha Fetoprotein （AFP), and radiological
             images proposed by Liver Cancer Society, Chinese Anti-Cancer Association;

          2. no clinically distant metastasis;

          3. Child Push score A,technically unresectable, or medically inoperable; maximal tumor
             size is less than 12 cm;

          4. age ≥ 18 and &lt;80 years of age;

          5. Karnofsky Performance Score ≥ 70;

          6. No previous invasive cancer (within 5 years before the HCC diagnosis)except for skin
             non-melanoma cancer or non muscle invasive bladder cancer; Ability to understand
             character and individual consequences of the clinical trial;

          7. Willing to sign the written informed consent; Informed consent must be signed before
             the enrollment in the trial;

        Exclusion Criteria:

          1. Distant metastasis (M1);

          2. maximal tumor size is more than 12 cm;

          3. tumor invading adjacent gastrointestine (T4);

          4. Child push score B or C;

          5. Previous hepatic radiotherapy;

          6. Severe systemic disorders;

          7. Previous malignancy (within 5 years) except for skin non-melanoma cancer or 3-year
             disease free interval from previous malignancy like in situ cervix cancer or non
             muscle invasive bladder cancer;

          8. Non conformity of the radiotherapy dose distribution when compared to the dose
             constraints;

          9. Psychiatric disorders or any other condition that can make unreliable the informed
             consent;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>guoliang Jiang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zheng Wang, MD</last_name>
    <phone>+86-38296666-53609</phone>
    <email>zheng.wang@sphic.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>weixiang Qi, MD</last_name>
    <phone>+86-38296666-53607</phone>
    <email>weixiang.qi@sphic.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zheng wang, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>zheng.wang@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>weixiang Qi, MD</last_name>
      <phone>+86-021-38296666-53609</phone>
      <email>weixiang.qi@sphic.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>guoliang Jiang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2016</study_first_submitted>
  <study_first_submitted_qc>June 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 18, 2016</last_update_submitted>
  <last_update_submitted_qc>June 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Guoliang Jiang</investigator_full_name>
    <investigator_title>Director the committee of clinical technique</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>carbon-ion radiotherapy</keyword>
  <keyword>toxicity</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

